cytarabine and ER-Negative PR-Negative HER2-Negative Breast Cancer

cytarabine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aittomäki, K; Blomqvist, C; Carpén, O; Fagerholm, R; Heikkilä, P; Heikkinen, T; Khan, S; Korpela, T; Nevanlinna, H1

Other Studies

1 other study(ies) available for cytarabine and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.
    Breast cancer research and treatment, 2013, Volume: 141, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Eukaryotic Initiation Factor-4E; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Proteins; Paraffin Embedding; Phenotype; Prognosis; Protein Biosynthesis; Tissue Array Analysis; Treatment Outcome; Triple Negative Breast Neoplasms

2013